Introduction {#section5-2050312120923177}
============

Osteosarcoma is the most common malignant tumor of the bone and is derived from primitive mesenchymal cells. Usually, the tumors originate from bone and rarely from soft tissue.^[@bibr1-2050312120923177]^ Osteosarcoma commonly affects children, adolescents, and young adults and accounts for 15% of all solid cancers in this age group.^[@bibr1-2050312120923177][@bibr2-2050312120923177]--[@bibr3-2050312120923177]^ Although the survival rate of patients with osteosarcoma has been extremely poor in the past few decades, it has dramatically improved with the establishment of chemotherapy.^[@bibr4-2050312120923177]^ In general, cisplatin, doxorubicin, high-dose methotrexate, and ifosfamide are considered the active agents against osteosarcoma.^[@bibr1-2050312120923177]^ Advances in biomedical engineering have led to a major shift toward limb-preserving surgery instead of amputation surgery. Options for reconstruction after limb-preserving tumor resections include endoprosthetic implants or reconstruction by liquid nitrogen. In this way, surgical treatments have also improved the quality of life of the survivors, mainly because of preservation surgeries performed for the extremities to preserve the affected limbs.^[@bibr5-2050312120923177]^ These findings show that the treatment for osteosarcoma is evolving. Although new treatment approaches have been developed, thus far, no curative treatment protocol for patients with unresectable osteosarcomas has been developed. Therefore, treatment strategies have room for improvement.^[@bibr1-2050312120923177],[@bibr6-2050312120923177]^ Most recently, heavy particle radiation (HPR) therapy has been used to treat osteosarcoma.^[@bibr7-2050312120923177]^ However, there have been a few reports on the outcomes of HPR treatment for resectable or unresectable osteosarcoma.^[@bibr7-2050312120923177]^ This study aimed to investigate the results of treatments in osteosarcoma patients treated comprehensively in our department.

Patients and methods {#section6-2050312120923177}
====================

The present retrospective study evaluated 12 patients (eight men and four women) with osteosarcoma who were treated in our department from March 2012 to March 2017 ([Table 1](#table1-2050312120923177){ref-type="table"}). The median age of the patients was 22.5 years (range 8--74 years), and the average follow-up period was 39.5 months (range 10--84 months). The tumor site, tissue type, stage, treatments, postoperative limb function, effects and side effects of chemotherapy, surgical margin, survival, and final outcomes were researched. Patients with poor prognosis were evaluated in depth. The Enneking staging system was used for staging the disease,^[@bibr8-2050312120923177]^ and adverse effects were assessed using the National Cancer Institute Common Toxicity Criteria (version 1).^[@bibr9-2050312120923177]^ The surgical margins in the resected specimens were categorized as R0, R1, or R2 based on previous classifications.^[@bibr10-2050312120923177]^ The Musculoskeletal Tumor Society (MSTS) score was used for limb function evaluation.^[@bibr11-2050312120923177]^ The survival rate and event-free survival were calculated. The biopsies assessed in this study were all from patients with osteosarcoma treated at our hospital. All patients provided written informed consent to be included in this study.

###### 

Clinical features of patients with primary osteosarcoma treated comprehensively in our department.

![](10.1177_2050312120923177-table1)

  Patient number   Age (years)/sex   Site      Histological type   Stage   Treatment     Surgical margin   CT         CT response   Local recurrence   Metastasis   Metastasectomy   Follow-up (months)   Outcome
  ---------------- ----------------- --------- ------------------- ------- ------------- ----------------- ---------- ------------- ------------------ ------------ ---------------- -------------------- ---------
  1                17/M              Tibia     Conventional        3       CT, WR        R1                NECO-95J   SD            \+                 \+           −                43                   DOD
  2                32/M              Pelvic    Conventional        2B      CT, HPR       --                NECO-95J   PR            −                  \+           \+               55                   AWD
  3                8/M               Humerus   Fibroblastic        3       CT, WR, VBG   R0                NECO-95J   PR            −                  −            −                29                   CDF
  4                52/M              Pelvic    Conventional        2B      CT, WR, HPR   R1                NECO-95J   PD            \+                 −            −                32                   AWD
  5                28/F              Sacrum    Chondroblastic      2B      CT, HPR       --                NECO-95J   PD            −                  −            −                10                   DOD
  6                14/M              Femur     Conventional        2A      CT, WR        R0                NECO-95J   CR            −                  −            −                24                   CDF
  7                13/F              Femur     Conventional        2B      CT, WR        R0                NECO-95J   PD            −                  −            −                65                   CDF
  8                15/F              Femur     Osteoblastic        2A      CT, WR        R0                NECO-95J   SD            −                  −            −                84                   CDF
  9                36/F              Tibia     Chondroblastic      2A      CT, WR        R0                NECO-95J   SD            −                  −            −                40                   CDF
  10               51/M              Humerus   Conventional        1A      CT, WR        R0                IA         SD            −                  −            −                44                   CDF
  11               74/F              Radius    Fibroblastic        2B      CT, WR, LNB   R0                IA         SD            −                  −            −                14                   CDF
  12               16/M              Tibia     Conventional        2B      CT, WR, LNB   R0                NECO-95J   PD            −                  −            −                39                   CDF

NECO-95J: neoadjuvant chemotherapy for osteosarcoma -- 95J; SD: stable disease; DOD: dead of the disease; HPR: heavy particle radiation; AWD: alive with disease; CDF: continuously disease-free; PD: progressive disease; IA: ifosfamide and doxorubicin; CR: complete response; PR: partial response; VBG: vascularized bone graft; LNB: liquid nitrogen treated bone; WR: wide resection; CT: chemotherapy.

Statistical analysis {#section7-2050312120923177}
--------------------

The survival rate was determined using the Kaplan--Meier method. Statistical analysis was performed with StatMate (ATMS, Tokyo, Japan) software for Windows, version 5.01 as previously described.^[@bibr12-2050312120923177]^

Results {#section8-2050312120923177}
=======

The tumor sites included the femur (n = 4), pelvis (n = 2), tibia (n = 3), humerus (n = 2), and radius (n = 1). Based on the histopathology, seven cases were classified as conventional, two as fibroblastic, two as chondroblastic, and one as an osteoblastic tumor. Among the 12 patients, one, three, six, and two patients had stage 1A, 2A, 2B, and 3 tumors, respectively. The treatments administered included chemotherapy, wide resection, and artificial joint replacement ([Table 1](#table1-2050312120923177){ref-type="table"}). All enrolled patients received chemotherapy (10 patients: NECO-95J protocol^[@bibr13-2050312120923177]^ and two patients: IA (ifosfamide and doxorubicin)). As surgical treatment, wide resection was performed in 10 cases. HPR was performed in the other two cases. For reconstruction, tumor-type arthroplasty was performed in six cases. Vascularized fibular bone graft was also performed in one case. Moreover, liquid nitrogen--treated bone was used in two cases. The MSTS scores (survey of nine cases with extremity reconstruction) were excellent for seven patients and good for two patients. The 3-year survival rate was 73.3% ([Figure 1](#fig1-2050312120923177){ref-type="fig"}). The event-free survival rate was 66% ([Figure 2](#fig2-2050312120923177){ref-type="fig"}). The outcomes of chemotherapy (with magnetic resonance imaging (MRI))^[@bibr14-2050312120923177]^ included the following: complete response in one patient, partial response in two patients, stable disease (SD) in five patients, and progressive disease (PD) in four patients. The adverse events included mild to moderate neutropenia in all 12 patients and moderate kidney disorder (tubule injury) in two patients. No irreversible side effects were observed. The surgical margin was evaluated in 10 patients who underwent wide resection. While a positive microscopic margin (R1) was observed in two patients, a negative margin (R0) was seen in the other eight patients. One patient who underwent surgery with liquid nitrogen treatment developed a fracture 22 months after the first operation. Revision surgery was performed, which resulted in a non-union joint. Ten patients were found to be continuously disease-free (CDF). Of the two patients treated with chemotherapy and heavy ion beam irradiation, one was alive with disease (AWD; living with lung metastasis), while the other was dead of the disease (DOD). Of the two patients treated with heavy ion beam irradiation without surgery, one had two tumors. One tumor exhibited PD as evaluated by MRI after heavy ion beam irradiation, and the other exhibited SD. One patient still had a remaining tumor mass in the retroperitoneum and the other had lung metastasis after HPR. Therefore, both patients after HPR were not eligible for surgical treatment. In the other patient, a lung metastasis was detected 19 months after treatment, for which lower lobular resection was performed. Lung metastasis recurred, and a partial metastasectomy was performed, following which no more metastasis has been observed. The two patients who were AWD (including one patient with recurrence and another with lung metastasis) and two who were DOD were evaluated in greater detail. Three of these four patients (75%) had tumors in the pelvic region, and the tumor in the fourth patient originated in the tibia. The tumors originating in the tibia all had a positive microscopic margin (R1). Tumors in two of these four patients were unresectable because invasion around the main tumor was observed, whereas they were resectable in the other two patients.

![Kaplan--Meier curves showing the survival rate. The 3-year survival rate was 73.3%.](10.1177_2050312120923177-fig1){#fig1-2050312120923177}

![Kaplan--Meier curves showing the event-free survival rate. The 3-year event-free survival was 66%.](10.1177_2050312120923177-fig2){#fig2-2050312120923177}

Discussion {#section9-2050312120923177}
==========

In our hospital, osteosarcoma patients are treated comprehensively for limb preservation. In this study, we evaluated the clinical outcomes of these treatments and found them to be favorable. Consistent with the results of previous studies, histologically, the common types of osteosarcomas seen were conventional, fibroblastic, and chondroblastic,^[@bibr13-2050312120923177]^ and the most common stage was the Enneking stage 2B.^[@bibr5-2050312120923177],[@bibr15-2050312120923177]^

Recent studies have shown that the 5-year survival rate for primary osteosarcomas is approximately 65%--70%,^[@bibr16-2050312120923177],[@bibr17-2050312120923177]^ although a survival rate of approximately 90% has also been reported.^[@bibr18-2050312120923177]^ Recent advances in chemotherapy and surgical treatments for osteosarcoma have improved the survival rates compared to those in the 1970s.^[@bibr19-2050312120923177]^ One more most recent study showed that the 3-year survival rate was 79%^[@bibr20-2050312120923177]^ and the event-free survival rate at 3 years was 69.5%.^[@bibr21-2050312120923177]^ Similarly, in our hospital, the event-free survival rate at 3 years was 66% and the 3-year survival rate was 73.3%, with eight of the 10 cases that were originally resectable showing good outcomes (CDF). These findings suggest that osteosarcoma has been appropriately treated by a multidisciplinary approach and is expected to be curable.

According to a recent meta-analysis, the methotrexate, doxorubicin, and cisplatin regimen remains the preferred option for osteosarcoma chemotherapy.^[@bibr22-2050312120923177]^ The most common grade 3/4 adverse event reported is neutropenia.^[@bibr22-2050312120923177]^ Ten of the 12 patients in our study were administered chemotherapy according to the NECO-95J protocol, which resulted in a good histological response, was comparable to induction chemotherapy, and had a favorable overall survival^[@bibr23-2050312120923177]^ (78.7%). Elderly patients were treated using the IA protocol. We observed no irreversible adverse events ([Table 2](#table2-2050312120923177){ref-type="table"}).

###### 

Chemotherapy toxic effects, worst grade per patient.

![](10.1177_2050312120923177-table2)

                       Grade 0   Grade 1   Grade 2   Grade 3   Grade 4
  -------------------- --------- --------- --------- --------- ---------
  Hematological                                                
   White blood cells   1         4         4         3         0
   Neutrophils         0         5         4         3         0
   Platelets           11        1         0         0         0
  Biochemical                                                  
   Creatinine          0         2         1         0         0
   AST                 10        1         1         0         0
   ALT                 9         3         0         0         0
  Clinical                                                     
   Nausea              10        2         0         0         0
   Vomiting            3         0         0         0         0
   Diarrhea            1         0         0         0         0
   Mucositis           0         0         0         0         0
   Alopecia            12        0         0         0         0
   Fever               2         0         0         0         0
   Infection           0         0         0         0         0
   Neurological        0         0         0         0         0
   Cardiac             0         0         0         0         0

AST: aspartate aminotransferase; ALT: alanine aminotransferase.

Tumor-type arthroplasty and liquid nitrogen treatment are the common methods used for reconstruction after wide resection.^[@bibr24-2050312120923177]^ In the past few decades, limb salvage surgery has evolved,^[@bibr5-2050312120923177],[@bibr25-2050312120923177]^ and good limb function has been reported after remodeling using both tumor-type joint replacement and liquid nitrogen treatment of the bone (95% MSTS score: ⩾good).^[@bibr5-2050312120923177],[@bibr26-2050312120923177],[@bibr27-2050312120923177]^ With tumor-type arthroplasty, revision surgery is usually needed for a long-term follow-up, especially if the patient is a child.^[@bibr28-2050312120923177]^ In this study, none of the patients who underwent arthroplasty required revision surgery. The MSTS score after tumor arthroplasty was generally good. However, with liquid nitrogen treatment, bone fractures, infections, soft tissue recurrences, and nerve palsy have been reported as surgical complications.^[@bibr29-2050312120923177]^ Fractures and bone non-union are common following liquid nitrogen--treated bone reconstruction.^[@bibr30-2050312120923177]^ Liquid nitrogen--treated bone combined with vascularized fibular bone graft has been shown to form a better union,^[@bibr31-2050312120923177]^ but, in this study, the patient who underwent this treatment had a fracture and finally non-union.

The 5-year survival rate for osteosarcomas occurring in unresectable sites is estimated to be almost 0%.^[@bibr32-2050312120923177]^ In contrast, the 5-year survival rate for patients with unresectable osteosarcomas treated with heavy particle radiotherapy is 33%.^[@bibr33-2050312120923177]^ However, the effects of this treatment could not be determined in our institution.

In general, osteosarcomas metastasize mainly to the lungs.^[@bibr34-2050312120923177]^ Previous studies have reported that approximately 10%--50% of osteosarcoma patients have lung metastasis at diagnosis,^[@bibr14-2050312120923177],[@bibr35-2050312120923177],[@bibr36-2050312120923177]^ while another study reported that the incidence of lung metastasis in osteosarcoma patients is approximately 15%.^[@bibr37-2050312120923177]^ Lung metastasis has a significant impact on the prognosis of osteosarcoma patients.^[@bibr34-2050312120923177]^ Surgery and chemotherapy can significantly improve the survival of patients with metastases.^[@bibr34-2050312120923177]^ In 2008, Chen et al.^[@bibr38-2050312120923177]^ estimated that the 5-year survival rate of osteosarcoma patients with lung metastasis treated by pulmonary metastasectomy was 31%. In this study, we had one patient with lung metastasis who was treated surgically and is AWD. These findings suggest that aggressive surgical treatments result in favorable outcomes.

Pelvic osteosarcoma has a higher rate of local recurrence than recurrence in the limbs.^[@bibr39-2050312120923177]^ In addition, inadequate margins can lead to poor prognosis.^[@bibr39-2050312120923177]^ Other studies have also shown that the recurrence rate of osteosarcomas with an inadequate margin (⩾R1) is high and leads to poor prognosis.^[@bibr40-2050312120923177]^ Moreover, given the same margin, pelvic osteosarcomas are more likely to recur locally than in the extremities.^[@bibr41-2050312120923177]^ In this study, pelvic osteosarcoma patients with inadequate margins (⩾R1) also had a poor prognosis.

The major limitation of this study is the small sample size. Due to the short follow-up period, the 5-year survival rate and event-free survival rate could not be calculated. In addition, the number of unresectable cases was small, and therefore, a comparison with resectable cases was not made. However, we could address clinical outcomes of patients with osteosarcoma treated comprehensively with HPR treatment. As the number of unresectable cases is expected to increase over time, further assessments can be done in the future.

Conclusion {#section10-2050312120923177}
==========

The treatment outcomes of osteosarcoma in our institution were good. Aggressive and comprehensive treatment of osteosarcomas provides a favorable prognosis.
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